| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Kidney Institute, University of Kansas Medical Center, 3901 Rainbow Boulevard, MS 3018, Kansas City, Kansas 66160, USA
(Requests for offprints should be addressed to S Liu; Email: sliu{at}kumc.edu)
* (S Liu and P S N Rowe contributed equally to this work) Inactivating PHEX (phosphate regulating gene with homologies to endopeptidases on the X chromosome) mutations cause X-linked hypophosphatemia in humans and mice (Hyp) through overproduction of fibroblast growth factor 23 (FGF23) a phosphaturic factor, by osteocytes. Matrix extracellular phosphoglycoprotein (MEPE) is also elevated in Hyp and other hypophosphatemic disorders. In addition, the administration of an ASARM (acidic serine–aspartate rich MEPE-associated motif) peptide derived from MEPE causes phosphaturia and inhibits bone mineralization in mice, suggesting that MEPE also plays a role in phosphate homeostasis. Since recent studies found that MEPE binds specifically to PHEX in vitro, we tested the effect of recombinant-MEPE and its ASARM peptide on PHEX enzyme activity in vitro and FGF23 expression in bone marrow stromal cell cultures ex vivo. We found that both recombinant MEPE and synthetic phosphorylated ASARM peptide (ASARM-PO4) inhibit PHEX enzyme activities in an in vitro fluorescent-quenched PHEX enzyme activity assay. The ASARM-PO4 peptide inhibits PHEX enzyme activity in a dose-dependent manner with a Ki of 128 nM and Vmax–i of 100%. Recombinant MEPE also inhibits PHEX activity (Ki = 2 nM and Vmax–i = 26%). Long-term bone marrow stromal cell cultures supplemented with 10 µ M ASARM-PO4 peptide resulted in significant elevation of FGF23 transcripts and inhibition of mineralization. These findings suggest that MEPE inhibits mineralization and PHEX activity and leads to increased FGF23 production. The resulting coordination of mineralization and release of a phosphaturic factor by MEPE may serve a physiological role in regulating systemic phosphate homeostasis to meet the needs for bone mineralization.
This article has been cited by other articles:
|
|
 |
|
  I. Ramon, P. Kleynen, J.-J. Body, and R. Karmali Fibroblast growth factor 23 and its role in phosphate homeostasis Eur. J. Endocrinol., January 1, 2010; 162(1): 1 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. David, A. Martin, A.-M. Hedge, and P. S. N. Rowe Matrix Extracellular Phosphoglycoprotein (MEPE) Is a New Bone Renal Hormone and Vascularization Modulator Endocrinology, September 1, 2009; 150(9): 4012 - 4023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Wesseling-Perry, R. C. Pereira, H. Wang, R. M. Elashoff, S. Sahney, B. Gales, H. Juppner, and I. B. Salusky Relationship between Plasma Fibroblast Growth Factor-23 Concentration and Bone Mineralization in Children with Renal Failure on Peritoneal Dialysis J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 511 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Marks, L. J. Churchill, E. S. Debnam, and R. J. Unwin Matrix Extracellular Phosphoglycoprotein Inhibits Phosphate Transport J. Am. Soc. Nephrol., December 1, 2008; 19(12): 2313 - 2320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Martin, V. David, J. S. Laurence, P. M. Schwarz, E. M. Lafer, A.-M. Hedge, and P. S. N. Rowe Degradation of MEPE, DMP1, and Release of SIBLING ASARM-Peptides (Minhibins): ASARM-Peptide(s) Are Directly Responsible for Defective Mineralization in HYP Endocrinology, April 1, 2008; 149(4): 1757 - 1772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Dobbie, R. J. Unwin, N. J. R. Faria, and D. G. Shirley Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption Nephrol. Dial. Transplant., February 1, 2008; 23(2): 730 - 733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Liu and L. D. Quarles How Fibroblast Growth Factor 23 Works J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1637 - 1647. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | CONTACT US | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
